BioInvent International AB (publ) reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was SEK 13.1 million compared to SEK 270.91 million a year ago. Net loss was SEK 88.35 million compared to net income of SEK 167.45 million a year ago. Basic loss per share from continuing operations was SEK 1.34 compared to basic earnings per share from continuing operations of SEK 2.86 a year ago. Diluted loss per share from continuing operations was SEK 1.34 compared to diluted earnings per share from continuing operations of SEK 2.86 a year ago.
For the six months, sales was SEK 29.35 million compared to SEK 287.57 million a year ago. Net loss was SEK 162.08 million compared to net income of SEK 99.7 million a year ago. Basic loss per share from continuing operations was SEK 2.47 compared to basic earnings per share from continuing operations of SEK 1.71 a year ago. Diluted loss per share from continuing operations was SEK 2.47 compared to diluted earnings per share from continuing operations of SEK 1.71 a year ago.